ACRS vs AKAM · rev $3.6M vs P/E 27, rev $2.17B
Aclaris Therapeutics Inc (ACRS) versus Akamai Technologies Inc (AKAM) — a side-by-side from cached financials, not a winner call.
Aclaris Therapeutics Inc (ACRS) is a biotechnology company listed on NASDAQ.
Akamai Technologies Inc (AKAM) is a software - infrastructure company listed on US.
Latest reported ACRS revenue for 2026-06-30 was $3.6M. Net income was -$41.3M. Revenue was up 81.6% from 2026-03-31 to 2026-06-30. ACRS currently screens at market cap $615.9M.
Latest reported AKAM revenue for 2026-06-30 was $2.17B. Net income was $185.7M. AKAM currently screens at market cap $11.31B and trailing P/E 26.7.
ACRS currently screens at market cap $615.9M. AKAM currently screens at market cap $11.31B and trailing P/E 26.7.
Not investment advice. Open the ACRS and AKAM stock pages for the full models.
Not investment advice.